BioSpace News Archive

ProSomnus, Inc. (“the Company”) (NASDAQ: OSA), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the publication of a peer-reviewed, independent, study in Military Medicine, in which 88% of patients with Obstructive Sleep Apnea (“OSA”) were successfully treated using the Company’s novel precision intraoral medical devices.

MiMedx Group, Inc. today announced that it has licensed worldwide exclusive rights to Turn Therapeutics’ proprietary antimicrobial technology platform, PermaFusion®, for the development of future biologic products focused on wound and surgical recovery applications.

Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2.

Promontory Therapeutics Inc. today presented Phase 2a clinical safety and efficacy data on lead therapeutic candidate PT-112 in combination with PD-L1 inhibition, in patients with advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2022.

Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors.

Alto Neuroscience Presents New Data Leveraging EEG and Machine Learning to Predict Individual Response to Antidepressants at the 61st Annual Meeting of the American College of Neuropsychopharmacology.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the Infectious Diseases Society of America.

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the creation of a dedicated center to enhance Emmes’ legacy and depth in cell and gene therapy research.

Anixa Biosciences, Inc. today announced the maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”) will host a conference call to discuss financial results for its fiscal fourth quarter and full fiscal year ended September 30, 2022, and provide a corporate update, on December 13, 2022 at 4:30 PM Eastern Time.